Evidence map›Paper›PMID 40194838›Full record

ArticleAnatomy & cell biology2025

Preconditioning enhances neurotrophic factor expression in rat bone marrow mesenchymal stem cells for neuroregenerative applications.

Sareh Pandamooz, Mohammad Ghasemian, Zahra Jamali, Maryam Hassanpour, Mohammad Javad Mokhtari, Shahrokh Zare, Mehdi Dianatpour, Mohammad Reza Jafarzadeh Shirazi, Mohammad Saied Salehi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anatomy & cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sareh PandamoozStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-6877-7102
Mohammad GhasemianStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0009-0007-6851-8497
Zahra JamaliStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0009-0009-4689-2095
Maryam HassanpourDepartment of Biology, Zarghan Branch, Islamic Azad University, Zarghan, Iran.ORCID https://orcid.org/0009-0006-9227-187X
Mohammad Javad MokhtariDepartment of Biology, Zarghan Branch, Islamic Azad University, Zarghan, Iran.ORCID https://orcid.org/0000-0001-5066-9632
Shahrokh ZareStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-4395-7844
Mehdi DianatpourStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0003-1217-9477
Mohammad Reza Jafarzadeh ShiraziDepartment of Animal Sciences, Shiraz University, Shiraz, Iran.ORCID https://orcid.org/0000-0001-8135-8597
Mohammad Saied SalehiDepartment of Animal Sciences, Shiraz University, Shiraz, Iran.ORCID https://orcid.org/0000-0002-3535-1578

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a leading cause of mortality and disability in adults worldwide. Among the various treatment strategies, cell-based therapies have gained considerable attention due to their regenerative potential. Enhancing the efficacy of stem cells is critical to improve therapeutic outcomes. Dimethyl fumarate (DMF) is one of the drugs that has been recognized for its ability to modulate the paracrine effects of stem cells. This study aimed to investigate the effect of different concentrations of DMF on rat bone marrow mesenchymal stem cells (BM-MSCs). The BM-MSCs viability following treatment with various doses of DMF was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and fluorescein diacetate staining at 24 and 72 hours. After identifying the optimal DMF concentration, BM-MSCs were cultured with selected DMF concentration for 72 hours, and their gene expression profiles of key neurotrophic factors were analyzed using quantitative real-time polymerase chain reaction. Our findings revealed that 1 μM DMF was the optimal concentration for enhancing BM-MSC viability. Treatment with this dose significantly upregulated the expression of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3, highlighting their potential in promoting neuronal support and regeneration. In contrast, the transcript level of glial-derived neurotrophic factor was significantly reduced, suggesting a selective regulatory effect of DMF on neurotrophic pathways. These findings shed light on the therapeutic promise of DMF in modulating neurotrophic factor expression in BM-MSCs, offering novel insights into its application in regenerative medicine for neurodegenerative conditions.

Indexed as

Dimethyl fumarateGrowth factorMesenchymal stem cellsPriming

Identifiers

PMID40194838
PMCPMC12178705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.